Recent News

  1. Jubilant DraxImage recently participated in the Family Health Campaign in which we joined industry advocates, leaders and professionals to raise awareness of the continuously growing impact of cardiovascular disease and the growing number of deaths associated with it – 1 in 4 deaths in the U.S. is caused by heart disease and (...)
  2. Legal action from Bracco Diagnostics, Inc. regarding patent infringement Montreal, QC, April 4, 2018 – Jubilant DraxImage Inc. (“DraxImage”), recently learned of legal challenges filed by Bracco Diagnostics, Inc. (“Bracco“) including a complaint filed with the U.S. International Trade Commission (ITC) regarding alleged patent infringement related to the Jubilant DraxImage (...)
  3. Jubilant DraxImage receives approval for new pulmonary indications from the U.S. Food and Drug Administration for DRAXIMAGE® DTPA Montreal, QC, December 27 2017 – Jubilant DraxImage Inc. (“DraxImage”), a Jubilant Pharma wholly-owned subsidiary, is pleased to announce approval of new pulmonary indications for DRAXIMAGE® DTPA (Kit for the Preparation of Technetium (...)
  4. 2nd Annual Miami Thyroid Oncology Symposium Thyroid Cancer Management in the Age of Genomics and Molecular Theranostics February 2-3, 2018 | Kovens Conference Center The 2nd Annual Miami Thyroid Oncology Symposium will highlight the changing paradigm in thyroid cancer management in the age of genomics and molecular diagnostic. Distinguished faculty (...)
  5. Jubilant DraxImage receives FDA approval for 12-Hour shelf-life for DRAXIMAGE® MAA Montreal, QC, October 26, 2017 – Jubilant DraxImage Inc. (“DraxImage”), a wholly-owned subsidiary of Jubilant Pharma, is pleased to announce the U.S. Food and Drug Administration (FDA) approval for the extension of the in-use shelf life of DRAXIMAGE® MAA (...)
  6. Jubilant DraxImage held an informative and interactive advisory panel  discussion on Cardiac PET with Rb-82 with moderator Dr. Gary Heller.  At the Jubilant DraxImage booth, various ASNC attendees were given demonstrations of the Rubidium Elution System.
  7. Jubilant Pharma Limited (“JPL”) a wholly owned subsidiary of Jubilant Life Sciences Ltd. through one of its subsidiaries announced today that it has signed an Agreement to acquire substantially all of the assets which comprise the radiopharmacy business of Triad Isotopes Inc. (“Triad”). See notification below.
  8. Michael Rossi is a significant addition with an impressive track record. Montreal, April 9, 2014 – Jubilant DraxIamge Inc., a Jubilant Life Sciences Company, is pleased to announce the appointment of Mr. Michael Rossi as Vice President, Sales and Business Operations, Jubilant DraxImage Inc., with effect from the 21st April 2014. (...)
  9. Jubilant DraxImage had significant presence at this year’s Mid-Winter meeting featuring important information on  V/Q imaging (MAA), Radioiodine therapy (HICON) and most importantly introducing its newest product approved by the USFDA; RubyFill.
  10. Jubilant Pharma, a solutions provider to global pharmaceutical customers, announced today it has appointed Michael Rossi as President of Jubilant DraxImage. Jubilant Pharma announced today it has appointed Michael Rossi as President of Jubilant DraxImage effective immediately. Michael will be responsible for leading the Jubilant DraxImage business, a subsidiary of (...)
  11. RUBY-FILL® is an approved cutting edge technology for PET myocardial perfusion imaging (MPI) under rest and pharmacological stress conditions to evaluate regional myocardial perfusion in adult patients with suspected or existing coronary artery disease. MONTREAL, Quebec – October 3, 2016 Jubilant DraxImage Inc., (“DraxImage”) a wholly Owned Subsidiary of Jubilant (...)
  12. JDI clarifies: no impact on supply from Chalk River shutdown JDI has received  enquiries from its customers with regards to our supply of I-131 following the announcement of the closure of the Chalk River reactor. JDI wishes to inform its customers purchasing JDI I-131 that JDI does not anticipate any (...)